What our clients say
Engaging Ichor has enabled us to variablize the fixed costs of operating a lab and dedicate our capital to scientific work. Ichor’s responsiveness and thoroughness are unmatched. We rely on their strategic guidance and competent experimental work; truly a partner rather than merely a vendor.
Ichor’s executive team has a unique talent for creative problem-solving and a goal-oriented approach to research. They have built and led several highly effective research initiatives for SENS Research Foundation, with a consistent focus on value creation and actionable endpoints.
Ichor has redefined effective implementation and quality assurance since I began working with them in 2014. Their emphasis on understanding project requirements, coupled with rigorous method development, elevate them head and shoulders above other CROs in the space.
View original article here. The State University of New York College of Environmental Science and Forestry (ESF) and Ichor Therapeutics are partnering to train graduate students in researching drugs that could combat age-related illnesses. The educational component will occur at ESF, where students will focus on biochemistry, chemistry or bioprocess engineering. Their laboratory research will […]
LAFAYETTE, NY: Today, Ichor Therapeutics, a biotechnology company that develops therapeutic interventions for age-associated disease, announced the formation of Grapeseed.Bio, a life science strategic fund and accelerator program. Through this program, life science entrepreneurs receive up to $100k in seed funding, technical training, full access to Ichor’s research laboratory, and mentorship in exchange for equity. […]
See original video here. LAFAYETTE, N.Y. (WSYR-TV) – A small biotech company in Central New York is getting a big shot in the arm from some British investors. Ichor Therapeutics is operating its high tech lab out of an office in LaFayette. The company has just received a $10 million investment from Juvenescence, which has offices […]
Read the original article here. July 12, 2018 LAFAYETTE, N.Y.–(BUSINESS WIRE)–Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of a joint venture with Juvenescence Limited. The joint venture, called FoxBio, Inc., will develop Antoxerene’s collection of small molecules that target senescent cells. Juvenescence […]